Patent · US Expired

Amido ether substituted imidazoquinolines

US7115622B2 · kind B2 · utility

70Cited by
55References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 28, 2005
Grant dateOct 3, 2006
Priority date
Expiry dateFeb 28, 2025

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/02
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.